|Year : 2020 | Volume
| Issue : 4 | Page : 237-238
Sharmila Devi Vadivelu
Department of Cornea, RIO GOH, Chennai, Tamil Nadu, India
|Date of Submission||04-Nov-2020|
|Date of Acceptance||24-Nov-2020|
|Date of Web Publication||16-Dec-2020|
Dr. Sharmila Devi Vadivelu
Department of Cornea, RIO GOH, Egmore, Chennai, Tamil Nadu
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Vadivelu SD. Editorial. TNOA J Ophthalmic Sci Res 2020;58:237-8
Dear Seniors and Friends,
I hope and pray that this message finds you and your loved ones, safe, and well.
The festival of lights was a brief but welcome respite from the pall of gloom cast by the pandemic. However, like every year the festival season brought, in its wake, a slew of firecracker injuries. Mercifully, though the nature and the severity of the injuries has remained the same, the number seems to have gone down significantly this year. The injuries reported, ranged from ocular surface burns to globe rupture. Interventions too, ranged from simple saline washes to complex surgical repairs and reconstructions. Many of these patients need long-term follow-up for late complications, such as secondary glaucomas. Choroidal detachment and hypotony maculopathy due to cyclodialysis were also reported.
Fireworks are a major preventable cause of ocular burns and shrapnel injuries especially in the pediatric age group. Health education, public awareness, and stricter legislation are essential to prevent firework related injuries. The single most effective measure would be to restrict firework displays to public spaces with appropriate safety measures. Regulating the quality of fireworks and promoting awareness of safety measures through the media and in schools will also go a long way in reducing the incidence of firecracker injuries.
The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 has thus far killed over 1.53 million people and infected approximately 66 million people throughout the world. Over the past 8 months, the number of cases has been rising exponentially in India. In order to tackle the situation, clinicians from various specialties including ophthalmology have been recruited, after a brief period of training, to treat COVID positive patients. Management protocols are changing at an astonishingly rapid pace. It is essential for us to remain updated, not only for us to do justice to our role as front line workers in COVID care centers, but also to be able to limit spread by identifying and isolating asymptomatic and mildly symptomatic health-care workers and patients during our routine duties in ophthalmology clinics. One of the confounding aspects of COVID-19 is the range of severity of the disease. While a large majority of patients have mild or no symptoms, a small proportion suffer acute respiratory distress syndrome and multi organ failure which is often fatal. Low lymphocyte counts, serum levels of CRP, D-dimers, ferritin, cardiac troponin, and interleukin-6 are all prognostic indicators used in risk stratification to predict severe and fatal COVID-19 in hospitalized patients. We have a COVID journal review in this issue along with the regular ophthalmic journal reviews. The International Severe Acute Respiratory and emerging Infections Consortium World Health Organization Clinical Characterisation Protocol UK study is an ongoing prospective cohort study which aims to develop and validate a pragmatic, clinically relevant risk stratification score that uses routinely available clinical information at hospital presentation to predict in-hospital mortality in patients admitted to hospital with COVID-19. The pragmatic 4C Mortality Score (where 4C stands for Coronavirus Clinical Characterisation Consortium) identified eight important predictors of mortality using generalized additive modeling with multiple imputed datasets: age, sex, number of comorbidities, respiratory rate, peripheral oxygen saturation, Glasgow coma scale, urea level, and C reactive protein. This article provides us with valuable directions for the future. The pandemic is here to stay, and its vital that we learn to convert severe COVID-19 into a manageable nonfatal infection.
We finally see some light at the end of the tunnel and good news from the United Kingdom (UK) gives us some hope. The Uk has become the first country to license a vaccine against COVID -19.It has approved the Pfizer /BioNtech coronavirus vaccine,paving the way for mass vaccination. Pfizer announcement may not have an immediate impact for India. Covishield ,developed by the Serum Institute of India (SII),is undergoing late -stage human trials in India .The news that a covid vaccine appears within reach is inspiring indeed.
Returning to this issue of the journal, we are pleased to bring you an interesting mix of articles from different subspecialties. The update on Dexamethasone implant by Dr. Jyothirmay Biswas and Dr. Richa Pyare from Sankara Netralaya is an interesting read. Dr. Jyotirmay Biswas, Director of uveitis and ocular pathology from Sankara Netralaya and Dr. M. Srinivasan, Director Emeritus, Aravind Eye care system have been listed among the top Indian researchers in a database of 100,000 scientists worldwide, created by a team of scientists at Stanford University, USA. It is a proud moment for all of us. We have some other interesting review articles including the one on Newer Anti-Vascular Endothelial Growth Factor Agents by Dr. Priya Chandrashekar and another on the current concepts in the management of cyclodialysis clefts, skillfully compiled by Dr. Vijayalakshmi Senthilkumar and Dr. Sharmila Rajendrababu. Also in this issue are several good original articles from different specialties as well as our regular features, the Quiz and the Journal review.
I wish to thank the authors who have contributed to this issue, the reviewers for meeting the deadlines, and the editorial board for their coordinated effort. We are happy to announce that the TNOA Journal of Ophthalmic sciences and research is now listed in the Directory of the Open access Journals (DOAJ). It is a proud and happy moment for all of us, let's all submit articles of higher scientific quality and may we reach greater heights of success in the coming years.
| References|| |
Zhang X, Tan Y, Ling Y, Lu G, Liu F, Yi Z, et al
. Viral and host factors related to the clinical outcome of COVID-19. Nature 2020;583:437-40.
Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, et al
. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Development and validation of the 4C Mortality Score. BMJ 2020;370:m3339.